Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

China Medical System Licenses Teikoku’s Lidoderm for Postherpetic Neuralgia in China

Fineline Cube Feb 13, 2026
Company Deals

Salubris Pharma Files Hong Kong IPO for Secondary Listing to Expand Cardiorenal Metabolic Franchise

Fineline Cube Feb 13, 2026
Company Deals

Immunofoco Bio Files Hong Kong IPO for Solid Tumor CAR-T Pipeline

Fineline Cube Feb 13, 2026
Company Deals

Ribo Life Science Licenses $4.4 Billion MASH siRNA Portfolio to Madrigal Pharmaceuticals

Fineline Cube Feb 12, 2026
Company Deals

Novartis Secures Long-Term Actinium-225 Supply from Niowave for Radioligand Therapy Expansion

Fineline Cube Feb 12, 2026
Policy / Regulatory

FDA Cracks Down on Compounded GLP-1 APIs; Novo Nordisk Sues Hims & Hers for Patent Infringement

Fineline Cube Feb 11, 2026
Company Drug

Amgen’s UPLIZNA Wins European Approval for Generalized Myasthenia Gravis

Fineline Cube Feb 13, 2026
Company Drug

Innovent Biologics Initiates Phase 3 HeriCare-Breast01 Study for IBI354 in HER2+ Breast Cancer

Fineline Cube Feb 13, 2026
Company Deals

Geneus Tech Secures Funding for Gseq500 Gene Sequencer Production

Fineline Cube Mar 2, 2023

Geneus Tech, a Shenzhen-based developer and manufacturer of gene sequencers, has reportedly raised an undisclosed...

Company Deals

Alphamab Oncology Partners with Stemirna for BsAb and mRNA Vaccine Development

Fineline Cube Mar 2, 2023

China-based Alphamab Oncology (HKG: 9966) has announced a strategic partnership with Shanghai-based mRNA drug developer...

Company Drug

CanSino Biologics’ Inhalable COVID-19 Vaccine Gets EUA in Indonesia

Fineline Cube Mar 2, 2023

China-based CanSino Biologics (SHA: 688185, HKG: 6185) has announced that it has received emergency use...

Company Deals

BeiGene Reports Outstanding Q4 and Full-Year 2022 Financial Results

Fineline Cube Mar 1, 2023

BeiGene, Ltd. (NASDAQ: BGNE, HKG: 6160, SHA: 688235) has released financial results for the Q4...

Company

Viatris Reports Q4 2022 Results, Highlights China Growth

Fineline Cube Mar 1, 2023

US-based generics giant Viatris Inc. (NASDAQ: VTRS) has released its Q4 2022 financial report. The...

Company Medical Device

China Performs First AB-BNCT Procedures Outside Japan

Fineline Cube Mar 1, 2023

The first accelerator-based boron neutron capture therapy (AB-BNCT) procedures have been performed in China by...

Company

HutchMed Reports 2022 Financial Results with Revenue Growth

Fineline Cube Mar 1, 2023

Hutchison China Meditech (HutchMed; HKG: 0013, NASDAQ: HCM) has released its financial results for the...

Company Drug

3SBio’s Nalfurafine Tablets Accepted for Review by NMPA for Chronic Liver Disease

Fineline Cube Mar 1, 2023

China-based 3SBio Inc. (HKG: 1530) has announced that a clinical trial filing for its nalfurafine...

Company Deals

3SBio Terminates Distribution Agreement with AstraZeneca for Byetta

Fineline Cube Mar 1, 2023

China-based 3SBio Inc. (HKG: 1530) has announced the termination of a distribution agreement with UK...

Company Drug

JW Therapeutics Initiates Clinical Study for JWATM214 in Advanced Hepatocellular Carcinoma

Fineline Cube Mar 1, 2023

China-based JW Therapeutics (HKG: 2126) has announced the initiation of a clinical study for its...

Company

FibroGen Reports Q4 2022 Financial Results with Revenue Growth

Fineline Cube Mar 1, 2023

US-based FibroGen Inc. (FGEN) has released its Q4 2022 financial results. The company reported global...

Policy / Regulatory R&D

China Issues New Ethical Review Measures for Life Sciences and Medical Research

Fineline Cube Mar 1, 2023

The National Health Commission, Ministry of Education, Ministry of Science and Technology, and National Administration...

Company

Bayer Reports 2022 Sales Growth, Highlights New Drug Performances

Fineline Cube Mar 1, 2023

Germany-based Bayer (ETR: BAYN) released its 2022 annual report this week, revealing a global sales...

Policy / Regulatory

China’s NRDL Update and Expansion of ‘Dual Channel’ Drug Access

Fineline Cube Mar 1, 2023

The latest update to China’s National Reimbursement Drug List (NRDL) was implemented from March 1,...

Policy / Regulatory

China’s State Council Unveils Plan for TCM Revitalization and Development

Fineline Cube Mar 1, 2023

The State Council has released the “Traditional Chinese Medicine (TCM) Revitalization and Development Major Projects...

Company Deals Digital Hospital

Topchoice Medical to Acquire 19% Stake in Heren Health for $72.2M

Fineline Cube Feb 28, 2023

China-based Topchoice Medical Investment Corp., (SHA: 600763) a leading medical service group, is set to...

Company Deals

Eluminex Biosciences Closes $40M Series B for Ophthalmic Innovations

Fineline Cube Feb 28, 2023

China-based ophthalmic biotech Eluminex Biosciences (Suzhou) Ltd has announced the closure of a Series B...

Company Deals

RinuaGene Raises $14.4M in Pre-Series A+ for mRNA Drug Development

Fineline Cube Feb 28, 2023

RinuaGene, an mRNA-based drug developer based in Suzhou, has reportedly raised close to RMB 100...

Company

Junshi Biosciences Reports 2022 Preliminary Earnings with Revenue Decline

Fineline Cube Feb 28, 2023

China-based Junshi Biosciences (HKG: 1877, SHA: 688180) has released its 2022 preliminary earnings estimate, indicating...

Company Deals

Chipscreen Biosciences Licenses First-in-Class BsAb YH008 from Eucure

Fineline Cube Feb 28, 2023

China-based biopharma Shenzhen Chipscreen Biosciences Co., Ltd (SHA: 688321) has announced a licensing agreement with...

Posts pagination

1 … 515 516 517 … 624

Recent updates

  • China Medical System Licenses Teikoku’s Lidoderm for Postherpetic Neuralgia in China
  • Organon Reports 2025 Revenue Decline to $6.2 Billion; JADA Sale and Portfolio Pressures Weigh
  • Salubris Pharma Files Hong Kong IPO for Secondary Listing to Expand Cardiorenal Metabolic Franchise
  • Sanofi Appoints Belén Garijo as New CEO to Drive R&D Innovation and Productivity
  • Immunofoco Bio Files Hong Kong IPO for Solid Tumor CAR-T Pipeline
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

China Medical System Licenses Teikoku’s Lidoderm for Postherpetic Neuralgia in China

Company

Organon Reports 2025 Revenue Decline to $6.2 Billion; JADA Sale and Portfolio Pressures Weigh

Company Deals

Salubris Pharma Files Hong Kong IPO for Secondary Listing to Expand Cardiorenal Metabolic Franchise

Company

Sanofi Appoints Belén Garijo as New CEO to Drive R&D Innovation and Productivity

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.